Impact of antibody framework residue VH-7I on the stability of a humanised anti-MUCI scFv and derived immunoenzyme

British Journal of Cancer

Volumn 90, Issue 9, 2004, Pages 1863-1870

  Krauss, J ^a,e   Arndt, M A E ^a,e   Zhu, Z ^a   Newton, D L ^a   Vu, B K ^a   Choudhry, V ^b   Darbha, R ^b   Ji, X ^b   Courtenay Luck, N S ^c,d   Deonarain, M P ^d   Richards, J ^d   Rybak, S M ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Antisoma plc   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Fusion protein; HMFGI; MUCI; Ribonuclease; scFv; Stability

Indexed keywords

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENETIC LINKAGE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOLECULAR DYNAMICS; MUTAGENESIS; PRIORITY JOURNAL; TUMOR CELL;

EID: 2642527816     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601759     Document Type: Article

References (49)

1. Aboud-Pirak E, Sergent T, Otte-Slachmuylder C, Abarca J, Trouet A, Schneider YJ (1988) Binding and endocytosis of a monoclonal antibody to a high molecular weight human milk fat globule membrane-associated antigen by cultured MCF-7 breast carcinoma cells. Cancer Res 48: 3188-3196
2. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM (1998) Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58: 485-490
3. Al-Yasi AR, Carroll MJ, Ellison D, Granowska M, Mather SJ, Wells CA, Carpenter R, Britton KE (2002) Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody hHMFGI. Br J Cancer 86: 870-878
4. Arndt MA, Krauss J, Schwarzenbacher R, Vu BK, Greene S, Rybak SM (2003) Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma. Int J Cancer 107: 822-829
5. Baldus SE, Monig SP, Hanisch FG, Zirbes TK, Flucke U, Oelert S, Zilkens G, Madejczik B, Thiele J, Schneider PM, Holscher AH, Dienes HP (2002) Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology 40: 440-449
6. Benedict CA, MacKrell AJ, Anderson WF (1997) Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods 201: 223-231
7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28: 235-242
8. Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S, Kanz L, Buhring HJ, Brugger W (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61: 6846-6850
9. Brünger AT, Rice LM (1997) Crystallographic refinement by simulated annealing: methods and applications. Methods Enzymol 277: 243-269
10. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289
11. Chen S, Le SY, Newton DL, Maizel Jr JV, Rybak SM (2000) A gender-specific mRNA encoding a cytotoxic ribonuclease contains a 3′ UTR of unusual length and structure. Nucleic Acids Res 28: 2375-2382
12. Chothia C, Gelfand I, Kister A (1998) Structural determinants in the sequences of immunoglobulin variable domain. J Mol Biol 278: 457-479
13. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ (1989) Conformations of immunoglobulin hypervariable regions. Nature 342: 877-883
14. Chothia C, Novotny J, Bruccoleri R, Karplus M (1985) Domain association in immunoglobulin molecules. The packing of variable domains. J Mol Biol 186: 651-663
15. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C (2000) Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10: 44-46
16. Esnouf RM (1997) An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J Mol Graphics Model 15: 112-113 132-134
17. Fleury D, Daniels RS, Skehel JJ, Knossow M, Bizebard T (2000) Structural evidence for recognition of a single epitope by two distinct antibodies. Proteins 40: 572-578
18. Foote J, Winter G (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224: 487-499
19. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823
20. Hanisch FG, Muller S (2000) MUC1: the polymorphic appearance of a human mucin. Glycobiology 10: 439-449
21. Henderikx P, Coolen-van Neer N, Jacobs A, van der Linden E, Arends JW, Mullberg J, Hoogenboom HR (2002) A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized. Am J Pathol 160: 1597-1608
22. Holmes MA, Buss TN, Foote J (2001) Structural effects of framework mutations on a humanized anti-lysozyme antibody. J Immunol 167: 296-301
23. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59
24. Hsiao KC, Bajorath J, Harris LJ (1994) Humanization of 60.3, an anti-CD18 antibody; importance of the L2 loop. Protein Eng 7: 815-822
25. Hursey M, Newton DL, Hansen HJ, Ruby D, Goldenberg DM, Rybak SM (2002) Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics. Leuk Lymphoma 43: 953-959
26. Jones TA, Kjeldgaard M (1997) Electron-density map interpretation. Methods Enzymol 277: 173-208
27. Kipriyanov SM, Kupriyanova OA, Little M, Moldenhauer G (1996) Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. J Immunol Methods 196: 51-62
28. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC, Bendig MM (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 8: 3-16
29. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G (1992) By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (NY) 10: 779-783
30. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222: 581-597
31. Martin AC, Thornton JM (1996) Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. J Mol Biol 263: 800-815
32. Merritt EA, Bacon DJ (1997) Raster3D: photorealistic molecular graphics. Methods Enzymol 277: 505-524
33. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, Shogen K (2002) Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20: 274-281
34. Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF, Whitlow M, Snoy P, Schlom J (1991) Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51: 6363-6371
35. Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM (1996) Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Biochemistry 35: 545-553
36. Nielsen UB, Adams GP, Weiner LM, Marks JD (2000) Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res 60: 6434-6440
37. Pei XY, Holliger P, Murzin AG, Williams RL (1997) The 2.0-Å resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci USA 94: 9637-9642
38. Price MR, Hudecz F, O'Sullivan C, Baldwin RW, Edwards PM, Tendler SJB (1990) Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 62: 795-802
39. Robinson CR, Sauer RT (1998) Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proc Natl Acad Sci USA 95: 5929-5934
40. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press
41. Suh SW, Bhat TN, Navia MA, Cohen GH, Rao DN, Rudikoff S, Davies DR (1986) The galactan-binding immunoglobulin Fab J539: an X-ray diffraction study at 2.6-Å resolution. Proteins 1: 74-80
42. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M (1999) MUC1 and cancer. Biochim Biophys Acta 1455: 301-313
43. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, Bodmer WF (1981) Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28: 17-21
44. Tramontano A, Chothia C, Lesk AM (1990) Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol 215: 175-182
45. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS, Sato E (1998) Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 4: 2605-2614
46. Verhoeyen ME, Saunders JA, Price MR, Marugg JD, Briggs S, Broderick EL, Eida SJ, Mooren AT, Badley RA (1993) Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. Immunology 78: 364-370
47. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Pluckthun A (1999) High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 59: 5758-5767
48. Xiang J, Sha Y, Jia Z, Prasad L, Delbaere LT (1995) Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. J Mol Biol 253: 385-390
49. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-3408